Hansa Biopharma AB (publ) reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was SEK 30.28 million compared to SEK 9 million a year ago. Net loss was SEK 138.44 million compared to SEK 103.93 million a year ago. Basic loss per share from continuing operations was SEK 3.11 compared to SEK 2.34 a year ago.